Press Releases & Statements
November 09, 2020
IPM Welcomes Exciting Results on Injectable HIV Prevention Option for Women
November 9, 2020—IPM welcomes today’s news that an injection of the antiretroviral drug cabotegravir administered every two months was found to be well-tolerated and highly effective in reducing... More »
July 24, 2020
In Milestone for Women’s HIV Prevention, European Medicines Agency Adopts Positive Opinion on Monthly Vaginal Ring to Reduce HIV Risk
IPM’s Dapivirine Ring Could Give Women in Sub-Saharan Africa First Long-Acting HIV Prevention Option; Opinion Paves Way for WHO and National Regulatory Reviews SILVER SPRING, Md. (July 24, 2020)—The... More »
June 05, 2020
IPM Statement: In Solidarity and Against Injustice
June 5, 2020—Over the past few months, we have found our lives disrupted by the novel coronavirus. Now we are confronting a much older and more insidious horror as we grapple with the deaths of... More »
June 13, 2019
Final Results of Open-label Study of IPM’s Dapivirine Vaginal Ring Show Increased Use and Suggest Lower Infection Rates Compared to Earlier Phase III Study
Durban (13 June 2019)—Final data from an open-label extension study of the monthly dapivirine ring show increased product use compared to a previous Phase III study. In addition, modeling data... More »
March 06, 2018
Interim Results of Open-Label Study of IPM’s Dapivirine Vaginal Ring Find Increased Product Use and Suggest Greater HIV Risk Reduction
Compared to earlier Phase III study, women’s adherence to monthly HIV prevention ring is higher and data suggest infection rates are lowerBOSTON (March 6, 2018) — Interim data from a large open-label... More »